Flutin Capsule 10 mg (Fluoxetine Hydrochloride)

Adult dosage

1. Depression 1) Initial treatment: The initial dose is 20 mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20–80 mg/day were administered. If no improvement is observed, an increase in the dose may be considered after several weeks. Doses exceeding 20 mg/day should be administered twice daily (morning and noon), and the maximum dose of 80 mg/day should not be exceeded. The onset of sufficient antidepressant effect may be delayed until 4 weeks or longer after starting treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this medicine. However, psychopharmacologists agree that acute symptoms of depression require drug treatment for several months or longer. It is not known whether the amount of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain improvement. 2. Bulimia nervosa Administer 60 mg/day of this medicine. Do not exceed 80 mg/day. Measure electrolyte levels before starting treatment. 3. Obsessive-compulsive disorder Administer 20–60 mg/day of this medicine. Do not exceed 80 mg/day. 4. Premenstrual dysphoric disorder Administer 20 mg/day of this medicine. Reassess the need for continued treatment after 6 months of therapy. - Patients with renal and/or hepatic impairment, patients receiving multiple medications, elderly patients, and patients with concomitant illnesses: Administer a lower dose or reduce the dosing frequency. Adjust the dose as appropriate according to age and symptoms. - Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, at least 5 weeks must elapse after discontinuing this medicine before starting an MAO inhibitor for the treatment of a psychiatric disorder. - Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization, other interventions should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If there is no alternative to linezolid or intravenous methylene blue and, for a particular patient, the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome, discontinue this medicine immediately and administer linezolid or intravenous methylene blue. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or for 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with methylene blue administered by non-intravenous routes (oral tablets or local injection), or with intravenous administration of this medicine at a dose of 1 mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the potential for emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used for the treatment of psychiatric disorders such as depression. It may increase the risk of suicidal thoughts or behaviors, especially in younger patients aged 18 to 24; hence, physicians should carefully evaluate the risks and benefits when prescribing this medication to this age group. Patients with hypersensitivity or severe renal impairment, and those taking certain types of medications such as MAO inhibitors, should not use this medication. Caution is necessary in patients with a history of seizures, and treatment should be discontinued immediately if seizures occur or their frequency increases. This medication may affect heart function; thus, patients with heart disease or those with abnormalities such as prolonged QT interval are encouraged to undergo an ECG before administration. Patients with impaired liver or kidney function may require dosage adjustment, and diabetic patients should be cautious with blood sugar control. Additionally, this medication can cause pupil dilation, so patients at risk of increased intraocular pressure or glaucoma should use it cautiously. Common side effects during administration may include headache, nausea, insomnia, fatigue, and diarrhea; if severe allergic reactions or skin rashes occur, medical attention should be sought immediately. Discontinuation of this medication suddenly may lead to withdrawal symptoms such as dizziness, sensory disturbances, anxiety, nausea, and tremors, so the dosage should be gradually reduced following a physician's guidance. Moreover, interactions with other medications, including antidepressants, may occur, so it is essential to consult healthcare professionals if taking or planning to take other medications. Women who are pregnant or breastfeeding should thoroughly discuss with their physician the potential effects of this medication on the fetus or newborn before taking it. Finally, safety has not been established for children and adolescents; thus, this medication is not recommended, and caution is also necessary for elderly patients. It is crucial to store this medication out of reach of children and not to transfer it to other containers.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reactions, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disorders, abnormal dreams, depersonalization, elevated mood, happy mood, thought disorders, abnormal libido, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal thoughts and behaviors, confusion, attention deficit, dizziness, taste disorders, somnolence, drowsiness, tremors, psychomotor agitation, movement disorders, ataxia, balance disorders, tics, seizures, inability to sit still, Buccglosal syndrome, serotonin syndrome, memory impairment, blurred vision, mydriasis, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary related events, epistaxis, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, hair loss, increased tendency for bruising, sweating, angioedema, petechiae, phototoxic reactions, purpura, erythema multiforme, arthralgia, myoclonus, myalgia, increased urinary frequency, dysuria, urinary retention, voiding dysfunction, gynecological bleeding, erectile dysfunction, ejaculation disorder, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, restlessness, chills, lethargy, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, suicidal ideation, suicidal behavior, fractures, withdrawal symptoms, dizziness, sensory disturbances, sleep disturbance, asthenia, restlessness, anxiety, tremors, headache, anaphylactoid reactions, gradual systemic reactions, severe reactions involving the skin, kidneys, liver, or lungs, weight loss, growth retardation, delayed puberty, hypoglycemia, changes in platelet function, aplastic anemia, atrial fibrillation, cataracts, cerebrovascular accidents, cholestatic jaundice, movement disorders, eosinophilic pneumonia, epithelial necrosis, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, worsening of movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior, inability to sit still, psychomotor agitation

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it is advisable to store it at room temperature, not too hot or too cold, between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication over time.

Appearance

A hard capsule with a green upper and lower part filled with a white or grayish powder.

Package unit

30 capsules/bottle, 100 capsules/bottle